ORTX - Orchard Therapeutics: Slow And Steady But Lacking Major Near-Term Catalysts
- I have covered ORTX multiple times in the last year, and the stock saw some steady gains.
- However, it does not have major catalysts in the next 6 months, excluding the EU launch which may not have immediate impact.
- The company has adequate cash until then.
For further details see:
Orchard Therapeutics: Slow And Steady, But Lacking Major Near-Term Catalysts